The Hillside Akathisia Scale: a Reliability Comparison of the English and German Versions

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 1991 Jan 1

PMID 1745708

Citations 3

Authors

W W Fleischhacker

C H Miller

P Schett

C Barnas

H Ehrmann

Affiliations

Soon will be listed here.

Abstract

Akathisia usually consists of two components, subjective restlessness and typical movements such as shuffling of the legs, pacing, shifting weight from one leg to the other, and rocking movements of the trunk. The ability to measure akathisia reliably is essential for the assessment of treatments for akathisia and for the evaluation of drug-induced side effects in general. To date, investigators have generally used self-constructed assessment scales without reporting data about reliability or validity. The Hillside Akathisia Scale (HAS) has two subjective and three objective items for which anchored rating points are provided. Reliability was 0.89 for the HAS total score. Reliability for rating subjective symptoms ranged from 0.86 to 0.92, and the objective scores ranged from 0.51 to 0.89. The correlation between HAS and a global assessment of akathisia (modified CGI) was 0.87. These values compare favorably with the original report on the scale indicating that the Hillside Akathisia Scale can validly quantify akathisia with a satisfactory degree of interrater reliability.

Citing Articles

Antipsychotic-induced akathisia in delirium: A systematic review.

Espi Forcen F, Matsoukas K, Alici Y Palliat Support Care. 2015; 14(1):77-84.

PMID: 26087817 PMC: 5516628. DOI: 10.1017/S1478951515000784.

Managing antipsychotic-induced acute and chronic akathisia.

Miller C, Fleischhacker W Drug Saf. 2000; 22(1):73-81.

PMID: 10647977 DOI: 10.2165/00002018-200022010-00006.

Extrapyramidal side effects of clozapine and haloperidol.

Kurz M, Hummer M, Oberbauer H, Fleischhacker W Psychopharmacology (Berl). 1995; 118(1):52-6.

PMID: 7597122 DOI: 10.1007/BF02245249.

References

Kramer M, Gorkin R, DiJohnson C, Sheves P . Propranolol in the treatment of neuroleptic-induced akathisia (NIA) in schizophrenics: a double-blind, placebo-controlled study. Biol Psychiatry. 1988; 24(7):823-7. DOI: 10.1016/0006-3223(88)90260-0. View

Van Putten T, MAY P, Marder S . Akathisia with haloperidol and thiothixene. Arch Gen Psychiatry. 1984; 41(11):1036-9. DOI: 10.1001/archpsyc.1983.01790220026004. View

Gibb W, Lees A . The clinical phenomenon of akathisia. J Neurol Neurosurg Psychiatry. 1986; 49(8):861-6. PMC: 1028945. DOI: 10.1136/jnnp.49.8.861. View

Fleischhacker W, Bergmann K, Perovich R, Pestreich L, Borenstein M, Lieberman J . The Hillside Akathisia Scale: a new rating instrument for neuroleptic-induced akathisia. Psychopharmacol Bull. 1989; 25(2):222-6. View

PATTERSON J . Lithium-induced akathisia. J Clin Psychopharmacol. 1988; 8(6):445. DOI: 10.1097/00004714-198812000-00022. View

Barnes T . A rating scale for drug-induced akathisia. Br J Psychiatry. 1989; 154:672-6. DOI: 10.1192/bjp.154.5.672. View

Braude W, Barnes T, Gore S . Clinical characteristics of akathisia. A systematic investigation of acute psychiatric inpatient admissions. Br J Psychiatry. 1983; 143:139-50. DOI: 10.1192/bjp.143.2.139. View

Miller C, Fleischhacker W, Ehrmann H, Kane J . Treatment of neuroleptic induced akathisia with the 5-HT2 antagonist ritanserin. Psychopharmacol Bull. 1990; 26(3):373-6. View

Dupuis B, Catteau J, Dumon J, Libert C, Petit H . Comparison of propranolol, sotalol, and betaxolol in the treatment of neuroleptic-induced akathisia. Am J Psychiatry. 1987; 144(6):802-5. DOI: 10.1176/ajp.144.6.802. View

10.

Bernick C . Methysergide-induced akathisia. Clin Neuropharmacol. 1988; 11(1):87-9. DOI: 10.1097/00002826-198802000-00010. View

11.

Adler L, Angrist B, Peselow E, Corwin J, Maslansky R, Rotrosen J . A controlled assessment of propranolol in the treatment of neuroleptic-induced akathisia. Br J Psychiatry. 1986; 149:42-5. DOI: 10.1192/bjp.149.1.42. View

12.

Bartels M, Heide K, Mann K, Schied H . Treatment of akathisia with lorazepam. An open clinical trial. Pharmacopsychiatry. 1987; 20(2):51-3. DOI: 10.1055/s-2007-1017074. View

13.

Fleischhacker W, Roth S, Kane J . The pharmacologic treatment of neuroleptic-induced akathisia. J Clin Psychopharmacol. 1990; 10(1):12-21. DOI: 10.1097/00004714-199002000-00003. View

14.

Adler L, Angrist B, Peselow E, Corwin J, Rotrosen J . Noradrenergic mechanisms in akathisia: treatment with propranolol and clonidine. Psychopharmacol Bull. 1987; 23(1):21-5. View

15.

Ratey J, Salzman C . Recognizing and managing akathisia. Hosp Community Psychiatry. 1984; 35(10):975-7. DOI: 10.1176/ps.35.10.975. View

16.

Shrout P, Fleiss J . Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979; 86(2):420-8. DOI: 10.1037//0033-2909.86.2.420. View

17.

Lipinski Jr J, Mallya G, Zimmerman P, Pope Jr H . Fluoxetine-induced akathisia: clinical and theoretical implications. J Clin Psychiatry. 1989; 50(9):339-42. View

18.

Friis T, Christensen T, Gerlach J . Sodium valproate and biperiden in neuroleptic-induced akathisia, parkinsonism and hyperkinesia. A double-blind cross-over study with placebo. Acta Psychiatr Scand. 1983; 67(3):178-87. DOI: 10.1111/j.1600-0447.1983.tb00339.x. View

19.

Shear M, Frances A, Weiden P . Suicide associated with akathisia and depot fluphenazine treatment. J Clin Psychopharmacol. 1983; 3(4):235-6. DOI: 10.1097/00004714-198308000-00006. View